Immatics Reports Clinical Responses across Multiple Solid Tumor Types in Ongoing ACTengine® IMA203 Phase 1a Trial Targeting PRAME
Dose escalation for cell therapy candidate ACTengine® IMA203 ongoing; dose level 3 completed at doses below 1 billio…
Dose escalation for cell therapy candidate ACTengine® IMA203 ongoing; dose level 3 completed at doses below 1 billio…
. Triumvira's T-cell antigen coupler (TAC-T cell) adoptive immunotherapy, TAC01-HER2, is manufactured using Lonza's Co…
T-knife Therapeutics, Inc., a next-generation T-cell receptor company developing a pipeline of innovative therapeutics f…
Eckert & Ziegler (ISIN DE0005659700, TecDAX) and Telix Pharmaceuticals (Telix) will cooperate closely in the commerciali…
Immatics’ second TCR Bispecifics program IMA402 demonstrates tumor cell killing in vitro and complete regressions of…
Allero Therapeutics BV, a Dutch oromucosal immunotherapy company, today announced the publication of two studies further…
Immatics’ first TCR Bispecific program IMA401 delivers preclinical proof-of-concept demonstrating complete remissions of…
Immatics Biotechnologies GmbH, a clinical-stage biopharmaceutical company active in the discovery and development of T-c…
Immatics today announced a collaboration with Roche to evaluate the safety and efficacy of IMA101, Immatics' investigati…
Clinical study demonstrates proof-of-concept for active personalized immunotherapy approach in a pioneering multi-center…